Finnegan Withdraws As Counsel In Hepatitis C Drug IP Row
By Kelly Knaub ( September 17, 2014, 3:27 PM EDT) -- A Delaware federal judge on Tuesday denied Gilead Sciences' motion to disqualify Finnegan Henderson Farabow Garrett & Dunner LLP from representing Idenix Pharmaceuticals Inc. as moot in a suit accusing Gilead of flouting several Idenix patents with its hepatitis C drug after the firm withdrew....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.